Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Zai Lab Ltd ( (HK:9688) ) has provided an update.
Zai Lab Limited announced that its Audit Committee will review and approve the unaudited condensed consolidated results for the six months ended June 30, 2025. These results, previously filed with the SEC, will be published in compliance with the Hong Kong Stock Exchange’s listing rules, including additional disclosures and a reconciliation from U.S. GAAP to IFRS. This action underscores Zai Lab’s commitment to transparency and adherence to international financial reporting standards, which may enhance investor confidence and align with global market practices.
The most recent analyst rating on (HK:9688) stock is a Buy with a HK$24.34 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative therapies. The company operates in the healthcare industry, primarily targeting unmet medical needs in oncology, autoimmune disorders, and infectious diseases.
Average Trading Volume: 16,051,317
Technical Sentiment Signal: Buy
Current Market Cap: HK$29.89B
For detailed information about 9688 stock, go to TipRanks’ Stock Analysis page.